Viking Therapeutics (VKTX) Research & Development (2014 - 2026)

Viking Therapeutics has reported Research & Development for 13 years, with the latest figure at $115.8 million in Q2 2026.

• Quarterly Research & Development rose 92.43% year-over-year to $115.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $509.3 million (up 227.92% YoY) and the FY2025 annual result came in at $345.0 million, up 239.38% from the prior year.
• Research & Development slipped to $115.8 million in Q2 2026 per VKTX's latest filing, from $150.2 million in the prior quarter.
• Over five years, Research & Development peaked at $153.5 million in Q4 2025 and troughed at $11.0 million in Q1 2023.
• A 5-year average of $46.1 million and a median of $23.3 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2025: Research & Development declined 12.32% in 2023, then soared 395.24% in 2025.
• Over 5 years, Research & Development stood at $16.2 million in 2022, then rose by 26.73% to $20.5 million in 2023, then surged by 51.14% to $31.0 million in 2024, then jumped by 395.24% to $153.5 million in 2025, then decreased by 24.57% to $115.8 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $115.8 million, $150.2 million, and $153.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.